Skip to main content

NICE IDs

11/10/2021
ID2710: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375)
11/10/2021
ID1596: Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly
11/10/2021
ID1625: Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma
11/10/2021
ID1631: Risdiplam for treating spinal muscular atrophy in children and adults
11/10/2021
ID1564: Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
11/10/2021
ID1609: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
11/10/2021
ID1604: Esketamine for treating major depressive disorder in adults at imminent risk for suicide
11/10/2021
ID1589: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
11/10/2021
ID945: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer
11/10/2021
ID3787: Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis
11/10/2021
ID1553: Cenobamate for focal onset seizures in epilepsy
11/10/2021
ID3802: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
11/10/2021
ID3734: Tralokinumab for treating moderate to severe atopic dermatitis
11/10/2021
ID2722: Belimumab for treating lupus nephritis
11/10/2021
ID1624: Berotralstat for preventing acute attacks of hereditary angioedema
11/10/2021
ID2731: Vericiguat for treating chronic heart failure with reduced ejection fraction
11/10/2021
ID1090: Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies
11/10/2021
ID3892: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
11/10/2021
ID2731: Vericiguat for treating chronic heart failure with reduced ejection fraction
11/10/2021
ID1083: Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia
Follow AWTTC: